Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 601–700 of 1,001
Zeiser, R. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_15 · Cited by 33
Zhang, Z., Kovalenko, P. L., Cui, M., DeSmet, M. L., Clinton, S. K., & Fleet, J. C. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22139 · Cited by 37
Burkitt‐Wright, E., & Kerr, B. A. (2010) · Archives of Disease in Childhood · doi:10.1136/adc.2009.160069 · Cited by 33
Wójcik, P., Kulig, J., Okoń, K., Zazula, M., Moździoch, I., Niepsuj, A., & Stachura, J. (2008) · PubMed · Cited by 36
Chen, J., Mikelis, C. M., Zhang, Y., Gutkind, J. S., & Zhang, B. (2013) · Oncotarget · doi:10.18632/oncotarget.813 · Cited by 32
The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future
Brandao, G., Brega, E. F., & Spatz, A. (2012) · Current Oncology · doi:10.3747/co.19.1058 · Cited by 35
State of Art of Cancer Pharmacogenomics in Latin American Populations
López‐Cortés, A., Guerrero, S. X., Redal, M. A., Alvarado, Á. T., & Quiñones, L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18060639 · Cited by 36
A Simply Modified Lymphocyte for Systematic Cancer Therapy
Zheng, D., Fan, J., Liu, X., Dong, X., Pan, P., Xu, L., & Zhang, X. (2018) · Advanced Materials · doi:10.1002/adma.201801622 · Cited by 32
Chou, Y. W., Hung, T.-C., Lin, Y.-T., Cheng, H.-W., Lin, J.-L., Lin, C.-H., Yu, C.-C., Chen, K., Yeh, T., & Chen, Y.-R. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0474-9 · Cited by 37
Annexin A6 is down-regulated through promoter methylation in gastric cancer.
Wang, X., Zhang, S., Zhang, J., Lam, E. K. Y., Liu, X., Sun, J., Feng, L., Lu, H., Yu, J. Q., & Jin, H. (2013) · Europe PMC (PubMed Central) · Cited by 32
Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas
Xia, Z., Zhang, N., Jin, H., Yu, Z., Xu, G., & Huang, Z. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.02.007 · Cited by 32
Epigenetic targeting of the Nanog pathway and signaling networks during chemical carcinogenesis
Tommasi, S., Zheng, A., Yoon, J., & Nia, A. B. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu026 · Cited by 34
Lorenz, S., Lißewski, C., Simsek-Kiper, P. O., Alanay, Y., Boduroğlu, K., Zenker, M., & Rosenberger, G. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt014 · Cited by 33
Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1
Li, H., Ung, C. Y., Xiao, H., Li, B. W., Low, B. C., Cao, Z. W., & Chen, Y. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn635 · Cited by 35
Tahara, M., Kiyota, N., Imai, H., Takahashi, S., Nishiyama, A., Tamura, S., Shimizu, Y., Kadowaki, S., Ito, K., Toyoshima, M., et al. (2024) · Thyroid · doi:10.1089/thy.2023.0547 · Cited by 41
A Pan-GTPase Inhibitor as a Molecular Probe
Hong, L., Guo, Y., BasuRay, S., Agola, J. O., Romero, E., Simpson, D. S., Schroeder, C. E., Simons, P. C., Waller, A., Garcia, M. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134317 · Cited by 34
Prakash, P., & Gorfe, A. A. (2014) · Molecular Simulation · doi:10.1080/08927022.2014.895000 · Cited by 32
Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis
Bigi, A., Beltrami, E., Trinei, M., Stendardo, M., Pelicci, P. G., & Giorgio, M. (2016) · Oncogene · doi:10.1038/onc.2016.42 · Cited by 32
Jhawat, V., Gulia, M., Gupta, S., Maddiboyina, B., & Dutt, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.039 · Cited by 36
Cucurull, M., Notario, L., Sánchez‐Céspedes, M., Hierro, C., Estival, A., Carcereny, E., & Saigí, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793121 · Cited by 35
“Lung adenocarcinoma (LuAD) is a type of cancer with the largest number of oncogenic alterations that are therapeutically approachable (4).”
BackgroundIntracellular lysyl oxidase: Effect of a specific inhibitor on nuclear mass in proliferating cells
Saad, F. A., Torres, M., Wang, H., & Graham, L. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.05.028 · Cited by 31
Ubiquitination: Added complexity in Ras and Rho family GTPase function
de la Vega, M., Burrows, J. F., & Johnston, J. A. (2011) · Small GTPases · doi:10.4161/sgtp.2.4.16707 · Cited by 37
Farschtschi, S. C., Mautner, V., Hollants, S., Hagel, C., Spaepen, M., Schulte, C., Legius, E., & Brems, H. (2015) · BMC Medical Genetics · doi:10.1186/s12881-015-0146-5 · Cited by 31
Blanc, L., Ciciotte, S. L., Gwynn, B., Hildick-Smith, G. J., Pierce, E. L., Soltis, K. A., Cooney, J. D., Paw, B. H., & Peters, L. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204948109 · Cited by 37
Kupzig, S., Bouyoucef, D., Yarwood, S., Sessions, R. B., & Cullen, P. J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00427-09 · Cited by 36
Pilocytic astrocytoma in a child with Noonan syndrome
Schuettpelz, L. G., McDonald, S., Whitesell, K., Desruisseau, D. M., Grange, D. K., Gurnett, C. A., & Wilson, D. B. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22193 · Cited by 33
Guo, Y., Parry, J. J., Laforest, R. A., Rogers, B. E., & Anderson, C. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118539 · Cited by 31
Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1127 · Cited by 30
Guo, G., Yao, G., Zhan, G., Hu, Y., Yue, M., Cheng, L., Liu, Y., Qi, Y., Qing, G., Zhang, Y., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.08.009 · Cited by 29
The impact of TP53 and RAS mutations on cerebellar glioblastomas
Milinković, V., Skender-Gazibara, M., Manojlović-Gačić, E., Gazibara, T. M., & Tanić, N. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.07.009 · Cited by 30
Rasopatías: trastornos del desarrollo con predisposición al cáncer y manifestaciones cutáneas
Hernández‐Martín, A., & Torrelo, A. (2011) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2011.02.010 · Cited by 34
koochak, A., Rakhshani, N., Niya, M. H. K., Tameshkel, F. S., Sohrabi, M., Babaee, M. R., Rezvani, H., Bahar, B., Imanzade, F., Zamani, F., et al. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.603 · Cited by 32
Enya, S., Kawakami, K., Suzuki, Y., & Kawaoka, S. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.032383 · Cited by 32
Zhang, B., Wang, O., Qin, J., Liu, S., Sun, S., Huitu, L., Kuang, J., Jiang, G., & Zhang, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083097 · Cited by 30
Baynes, R. D., & Gansert, J. L. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318199fa17 · Cited by 33
Rosenberger, G., Meien, S., & Kutsche, K. (2008) · Human Mutation · doi:10.1002/humu.20855 · Cited by 32
“…in CS vs. human cancers) consistently indicate that p.G12V has a stronger perturbing effect on HRAS function than p.G12S [Seeburg et al., 1984; Schubbert et al., 2007], we were not able to detect any difference in the amount of GTP-bound HRAS between fibroblast cells harboring p.G12S or…”
BackgroundThe promise of mTOR inhibitors in the treatment of colorectal cancer
Kim, D.-D., & Eng, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.721353 · Cited by 34
Romano, D., Maccario, H., Doherty, C., Quinn, N. P., Kölch, W., & Matallanas, D. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01414-12 · Cited by 31
Kim, C., Choi, Y. K., Lee, H., Ha, K., Won, M., Kwon, Y., & Kim, Y.-M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.063586 · Cited by 32
Zinsky, R., Bölükbas, S., Bartsch, H., Schirren, J., & Fisseler‐Eckhoff, A. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/789363 · Cited by 34
Li, T., Zheng, Y., Sun, H., Zhuang, R., Liu, J., Liu, T., & Cai, W. (2016) · Medical Oncology · doi:10.1007/s12032-016-0777-1 · Cited by 32
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Park, S., Kim, J.-Y., Lee, S., Suh, B., Keam, B., Kim, T. M., Kim, D., & Heo, D. S. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.299 · Cited by 30
Cancer drugs to treat birth defects
Wilkie, A. O. M. (2007) · Nature Genetics · doi:10.1038/ng0907-1057 · Cited by 31
Kaler, P., Sasazuki, T., Shirasawa, S., Augenlicht, L. H., & Klampfer, L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.01.010 · Cited by 34
Ras Modifies Proliferation and Invasiveness of Cells Expressing Human Papillomavirus Oncoproteins
Yoshida, S., Kajitani, N., Satsuka, A., Nakamura, H., & Sakai, H. (2008) · Journal of Virology · doi:10.1128/jvi.02363-07 · Cited by 31
Chen, J., Shen, Q. “., Labow, M., & Gaither, L. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3761 · Cited by 32
Noonan syndrome‐like disorder with loose anagen hair: A second case with neuroblastoma
Garavelli, L., Cordeddu, V., Errico, S., Bertolini, P., Street, M. E., Rosato, S., Pollazzon, M., Wischmeijer, A., Ivanovski, I. P., Daniele, P., et al. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37082 · Cited by 28
Wang, Z., Cui, J., Song, J., Wang, H., Gao, K., Qiu, X., Gou, M., Li, X., Hu, Z., Wang, X., et al. (2018) · Marine Biotechnology · doi:10.1007/s10126-018-9796-6 · Cited by 29
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“Strong oncogenic mutations block GAP catalytic activity, retaining the active GTP-bound state, thus promoting downstream signaling and cell proliferation as in the case of G12DK-Ras4Bmutant (Adjei, 2001; Schubbert et al., 2007; Smith and Ikura, 2014; Smith et al., 2013; Vigil et al., 2010).”
BackgroundPredictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC)
Stintzing, S., Stremitzer, S., Sebio, A., & Lenz, H. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.009 · Cited by 33
Ekvall, S., Hagenäs, L., Allanson, J. E., Annerén, G., & Bondeson, M.-L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33987 · Cited by 32
Mukhopadhyay, A., Krishnaswami, S. R., & Yu, B. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.296 · Cited by 30
“Activation of RAS can be modulated at many levels, including amount and availability of ligands, receptors, adaptors, and downstream effectors (Reuther and Der, 2000; Schubbert et al., 2007).”
BackgroundRole of ES Cell-Expressed Ras (ERas) in Tumorigenicity of Gastric Cancer
Kubota, E., Kataoka, H., Aoyama, M., Mizoshita, T., Mori, Y., Shimura, T., Tanaka, M., Sasaki, M., Takahashi, S., Asai, K., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091056 · Cited by 29
Khan, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i11.2979 · Cited by 32
Pyakurel, A., Balmer, D., Saba-El-Leil, M. K., Kizilyaprak, C., Daraspe, J., Humbel, B. M., Voisin, L., Le, Y. Z., von Lintig, J., Meloche, S., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00295-17 · Cited by 20
Methylation epigenotypes and genetic features in colorectal laterally spreading tumors
Sakai, E., Ohata, K., Chiba, H., Matsuhashi, N., Doi, N., Fukushima, J., Endo, H., Takahashi, H., Tsuji, S., Yagi, K., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28814 · Cited by 29
Hao, C., Wei, S., Tong, Z., Li, S., Shi, Y., Wang, X., & Zhu, Z.-H. (2012) · Tumor Biology · doi:10.1007/s13277-012-0358-7 · Cited by 28
The prognostic value of KRAS mutations in patients with colorectal cancer
Inoue, Y., Saigusa, S., IWATA, T., Okugawa, Y., Toiyama, Y., Tanaka, K., Uchida, K., Mohri, Y., & Kusunoki, M. (2012) · Oncology Reports · doi:10.3892/or.2012.1974 · Cited by 31
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Shieh, A., Ward, A. F., Donlan, K. L., Harding-Theobald, E. R., Xu, J., Mullighan, C. G., Zhang, C., Chen, S.-C., Su, X., Downing, J. R., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432252 · Cited by 31
Self-citationNew Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches
Rescigno, P., Cerillo, I., Ruocco, R., Condello, C., Placido, S. D., & Pensabene, M. (2013) · BioMed Research International · doi:10.1155/2013/852839 · Cited by 32
Kang, K., Zhang, J., Zhang, X., & Zhao, C. N. (2017) · Oncology Reports · doi:10.3892/or.2017.6074 · Cited by 30
RetractedSui, X., Chen, Y., Liu, B., Li, L., Huang, X., Wang, M., Wang, G., Gao, X., Zhang, L., Bao, X., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5622 · Cited by 29
A saturation-mutagenesis analysis of the interplay between stability and activation in Ras
Hidalgo, F., Nocka, L. M., Shah, N. H., Gorday, K., Latorraca, N. R., Bandaru, P., Templeton, S., Lee, D., Karandur, D., Pelton, J. G., et al. (2022) · eLife · doi:10.7554/elife.76595 · Cited by 28
“GTP-bound Ras binds to the Ras-binding domains (RBDs) of effector proteins, such as Raf kinases and PI-3 kinase (PI3K), triggering signaling cascades that result in cell proliferation ( Ehrhardt et al., 2002 ; Pylayeva-Gupta et al., 2011 ; Schubbert et al., 2007 ).”
LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis
Farncombe, K. M., Thain, E., Barnett, C., Sadeghian, H., & Kim, R. H. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01304-x · Cited by 29
“There are multiple genes that cause NS, all linked to the RAS/MAPK signalling pathway (4, 5).”
BackgroundChen, P., Li, W., Lü, Q., Wang, J., Yan, X., Zhang, Z., & Li, X. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-402 · Cited by 29
Specific Conformational States of Ras GTPase upon Effector Binding
Baussand, J., & Kleinjung, J. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct3007265 · Cited by 28
p120RasGAP-Mediated Activation of c-Src Is Critical for Oncogenic Ras to Induce Tumor Invasion
Chan, P.-C., & Chen, H.-C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3078 · Cited by 32
Kras in metastatic colorectal cancer
WICKI, A. N., Herrmann, R., & Christofori, G. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13112 · Cited by 34
Puliyappadamba, V. T., Thulasidasan, A. K. T., Vijayakurup, V., Antony, J., Bava, S. V., Shabna, A., Sundaram, S., & Anto, R. J. (2015) · BioFactors · doi:10.1002/biof.1244 · Cited by 28
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Caiola, E., Frapolli, R., Tomanelli, M., Valerio, R., Iezzi, A., Garassino, M. C., Broggini, M., & Marabese, M. (2018) · Scientific Reports · doi:10.1038/s41598-017-18900-y · Cited by 29
Buchmann, A., Karcier, Z., Schmid, B., Strathmann, J., & Schwarz, M. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.08.015 · Cited by 29
Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27584-x · Cited by 27
Yang, S.-H., Lin, H., Chang, V. H. S., Chen, C., Liu, Y., Wang, J., Zhang, K., Jiang, X., & Yen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4408 · Cited by 27
Quintás‐Cardama, A., Post, S. M., Solis, L. M., Xiong, S., Yang, P., Chen, N., Wistuba, I. I., Killary, A. M., & Lozano, G. (2014) · The Journal of Pathology · doi:10.1002/path.4385 · Cited by 31
Im, C., & Seo, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.5.174 · Cited by 27
Oncolytic Viruses for Multiple Myeloma Therapy
Calton, C. M., Kelly, K. R., Anwer, F., Carew, J. S., & Nawrocki, S. T. (2018) · Cancers · doi:10.3390/cancers10060198 · Cited by 28
Shimada, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Oyanagi, H., Okuda, S., Takabe, K., & Wakai, T. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.020 · Cited by 31
Small GTPases in platelet membrane trafficking
Walsh, T. G., Li, Y., Wersäll, A., & Poole, A. W. (2018) · Platelets · doi:10.1080/09537104.2018.1535703 · Cited by 28
Báez, R. V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73796 · Cited by 27
Hondo, N., Kitazawa, M., Koyama, M., Nakamura, S., Tokumaru, S., Miyazaki, S., Kataoka, M., Seharada, K., & Soejima, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216264 · Cited by 33
Vujic, I., Posch, C., Sanlorenzo, M., Yen, A., Tsumura, A., Kwong, A., Feichtenschlager, V., Lai, K., Arneson, D. V., Rappersberger, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2326 · Cited by 38
Sepe, L., Ferrari, M. C., Cantarella, C., Fioretti, F., & Paolella, G. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000343355 · Cited by 27
Personalized Biochemistry and Biophysics
Kroncke, B. M., Vanoye, C. G., Meiler, J., George, A. L., & Sanders, C. R. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00189 · Cited by 29
Complexity in KSR function revealed by Raf inhibitor and KSR structure studies
McKay, M., Freeman, A. K., & Morrison, D. K. (2011) · Small GTPases · doi:10.4161/sgtp.2.5.17740 · Cited by 27
A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death
Freeman, M. R., Kim, J., Lisanti, M. P., & Vizio, D. D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.11.18136 · Cited by 28
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 30
“This transforms Ras into a constitutively GTP-bound active oncoprotein, commonly termed ‘oncogenic Ras’ (Schubbert et al., 2007).”
BackgroundPreto, A., Gonçalves, J., Rebocho, A. P., Figueiredo, J., Meireles, A. M., Rocha, A. S., Vasconcelos, M. H., Seca, H., Seruca, R., Soares, P., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-387 · Cited by 28
Freedman, T. S., Sondermann, H., Kuchment, O., Friedland, G. D., Kortemme, T., & Kuriyan, J. (2009) · Structure · doi:10.1016/j.str.2008.11.004 · Cited by 30
Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota, T. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0660-4 · Cited by 33
Inhibiting the RAS–PI3K Pathway in Cancer Therapy
Sheridan, C., & Downward, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00005-6 · Cited by 28
A systematic comparison of copy number alterations in four types of female cancer
Kaveh, F., Baumbusch, L. O., Nebdal, D. J. H., Børresen‐Dale, A., Lingjærde, O. C., Edvardsen, H., Kristensen, V. N., & Solvang, H. K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2899-4 · Cited by 29
Multifunctionality of Calebin A in inflammation, chronic diseases and cancer
Brockmueller, A., Mueller, A., Kunnumakkara, A. B., Aggarwal, B. B., & Shakibaei, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962066 · Cited by 29
Cushman, I., & Casey, P. J. (2011) · Cell Adhesion & Migration · doi:10.4161/cam.5.1.13196 · Cited by 31
Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum
Pfeiffer, V., Götz, R., Xiang, C., Camarero, G., Braun, A., Zhang, Y., Blum, R., Heinsen, H., Nieswandt, B., & Rapp, U. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058259 · Cited by 28
Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder
Chung, E., Hsu, C.-L., & Kondo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028350 · Cited by 27
Kwok, C. W., Treeck, O., Buchholz, S., Seitz, S., Ortmann, O., & Engel, J. B. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0340-y · Cited by 26
Utx loss causes myeloid transformation
Zheng, L., Xu, L., Xu, Q., Yu, L., Zhao, D., Chen, P., Wang, W., Wang, Y., Han, G., & Chen, C. D. (2018) · Leukemia · doi:10.1038/s41375-018-0011-6 · Cited by 31
The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 32
“The Ras family of small GTPases, NRAS and KRAS, function as binary molecular switches by cycling between an active GTP-bound (RAS-GTP) and an inactive GDP-bound (RASGDP) confirmation that regulate downstream signaling effectors, such as Raf and PI3K (Schubbert et al. 2007).”
BackgroundBonnevaux, H., Lemaitre, O., Vincent, L., Levit, M. N., Windenberger, F., Halley, F., Delorme, C., Lengauer, C., García-Echeverría, C., & Virone-Oddos, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0496 · Cited by 33
Zhang, Y., Wang, Z., Ma, X., Yang, S., Hu, X., Tao, J., Hou, Y., & Bai, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.002 · Cited by 25
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.